72 results about "Fat accumulation" patented technology

Provided is a novel Lactobacillus fermentum strain (Accession No. KCTC 14106BP) and a composition for preventing or treating a metabolic disease including the same. A Lactobacillus fermentum according to the present invention may inhibit fat accumulation and increase anti-inflammatory cells in white adipose tissue. In addition, the Lactobacillus fermentum may effectively inhibit fat accumulation in brown adipose tissue and in liver tissue. The Lactobacillus fermentum strain may exhibit excellent blood glucose improvement effect, and in particular, may reduce a fasting blood glucose level. The Lactobacillus fermentum strain may effectively ameliorate insulin resistance by improving glucose tolerance and increasing insulin sensitivity. Therefore, the Lactobacillus fermentum strain may be usefully used to prevent or treat a metabolic disease such as obesity.

The invention provides an application of liquiritin in preparation of a PPAR gamma receptor partial agonist. Through a structure-based high-throughput virtual screening technology, it is found that liquiritin can be used as a partial agonist of a PPAR gamma receptor, and the relative activation efficiency of liquiritin is 35.9% of that of rosiglitazone; in-vitro experiments prove that liquiritin can remarkably promote glucose uptake and consumption of HepG2 cells and does not induce adipocyte differentiation; in-vivo experiments prove that liquiritin can effectively improve the blood glucose level of an insulin resistance mouse model induced by high fat diet and reduce the level of serum proinflammatory factors. Compared with thiazolidinedione compounds, liquiritin not only can relieve and treat insulin resistance or related metabolic diseases, but also does not cause adverse reactions such as weight gain, fat accumulation and myocardial hypertrophy, provides a new candidate compound for developing safe and effective anti-diabetic drugs, and has a wide application prospect.

The invention belongs to the technical field of traditional Chinese medicine research, and particularly relates to ganoderma lucidum polysaccharide and an extraction method and application thereof. The structural formula of the ganoderan is shown as a formula I in the specification. The ganoderan extracted by the invention can repair intestinal barriers by promoting the growth of beneficial intestinal bacteria, alleviate liver inflammation by targeting LPS / TLR4 / NF-kappa B / MAPK signal pathways, and reduce fat accumulation, thereby effectively alleviating the non-alcoholic fatty liver disease; and # imgabs0 #.

The application discloses a construction method of a fat-targeted gene therapy vector. The method comprises the following steps: obtaining a fat tissue-specific promoter sequence; obtaining a shRNA coding sequence targeting a Tks4 gene; cloning the promoter sequence and the shRNA coding sequence into an adeno-associated virus vector skeleton to construct a recombinant expression vector; and co-transfecting the recombinant expression vector and an auxiliary plasmid into a packaging cell to package and purify a recombinant adeno-associated virus particle. The vector constructed by the application adopts an adiponectin promoter to drive the expression of miR30-shRNA targeting the Tks4, and can be specifically expressed in fat tissues and livers after being injected through a tail vein, significantly inhibits fat cell hypertrophy and systemic fat accumulation induced by a high-fat diet, reduces the serum cholesterol level, does not cause an immune inflammatory reaction, does not affect sugar metabolism, and is not expressed in non-target tissues. The application provides a safe and efficient new strategy for the gene therapy of obesity, hyperlipidemia, fatty liver and related metabolic diseases.

The present invention addresses the problem of defining physiological significance and functions such as the influence of nicotinamide mononucleotide (NMN) contained in breast milk on the development of children. A composition for improving the athletic ability of a child is provided comprising a precursor of NAD. The improvement in athletic ability is preferably any one selected from the group consisting of promotion of skeletal muscle development and improvement in activity. A composition for reducing triglyceride levels in the blood of a child is provided comprising a precursor of NAD. A composition for reducing the blood glucose level in a child is provided comprising a precursor of NAD. A composition for inhibiting fat accumulation in children is provided, comprising a precursor of NAD.

The invention discloses a pediococcus pentosaceus MDL511, which is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.35201, the preservation date is July 11, 2025, and the classification name of the strain is pediococcus pentosaceus. The pediococcus pentosaceus MDL511 has the advantages that the preservation number is CGMCC No.35201, the preservation number is CGMCC No.35201, the preservation date is July 11, 2025, and the classification name of the strain is pediococcus pentosaceus. The pediococcus pentosaceus MDL511 disclosed by the invention can be used for remarkably reducing weight gain and fat growth of mice caused by high fat diet, reducing serum cholesterol, LDL-C (Low Density Lipoprotein Cholesterol) and ALT (Atomic Lymphocyte Transferase) levels and remarkably improving hepatic lesions and fat accumulation caused by high fat diet, so that the MDL511 has a blood fat reducing effect, can be used for preparing blood fat reducing products and weight losing products and has a good development prospect.

The invention aims to provide a peptide for accelerating fat metabolism and application thereof, the peptide is prepared into a product convenient to use, and the amino acid sequence of the peptide is MVHSYSETSD. The peptide is obtained through peptide library screening, bioinformatics analysis screening and fat cell decomposition experiment verification, and it is verified that the active peptide obtained through screening has the effects of accelerating fat metabolism, inhibiting fat accumulation, reducing blood fat and body fat content and reducing body weight; the insulin sensitivity and the glucose tolerance are improved, and the prevention and treatment effects on obesity and complications thereof are realized.

The application aims to provide a peptide for accelerating fat metabolism and application thereof, and to prepare the peptide into a product convenient to use, and the amino acid sequence of the peptide is MVHSYSETSD. The peptide is obtained through screening of a peptide library, screening through bioinformatics analysis, and verification through fat cell decomposition experiment, and the application verifies that the active peptide screened has the effect of accelerating fat metabolism, inhibiting fat accumulation, reducing blood fat and body fat content, reducing body weight, improving insulin sensitivity and glucose tolerance, and realizing the prevention and treatment effect on obesity and its complications.

The present invention provides a composition for alleviating fatty liver disease by using a single or complex extract of Sigesbeckia glabrescens and Luffa cylindrica, the composition exhibiting the activities of inhibiting fat accumulation and inflammation in liver cells without showing toxicity to liver cells, inhibiting fat accumulation and inflammation in liver tissue in high-fat-diet animal models, and increasing the expression of glutathione, which is a strong antioxidant in liver tissue.

The invention relates to the technical field of medicines, in particular to application of an integrin beta3 inhibitor RGDfK in preparation of a medicine for treating metabolic dysfunction related fatty liver diseases. The RGDfK provided by the invention can inhibit palmitoylation and membrane localization of CD36 in liver tissues of mice with fatty liver diseases related to metabolic dysfunction induced by high fat diet feeding, so that lipid uptake of the liver is inhibited. Experimental results show that RGDfK can improve obesity and insulin resistance of mice with metabolic dysfunction-related fatty liver diseases, can improve fat accumulation, fibrosis and inflammatory infiltration of liver tissues of the mice with fatty liver diseases, and is expected to become a new medicine for treating the metabolic dysfunction-related fatty liver diseases.

1. The name of the design product: anti-fat accumulation instrument. 2. The use of the design product: the design product is used for cosmetic instrument of massage, anti-fat accumulation and anti-wrinkle treatment. 3. The design points of the design product: in shape. 4. The picture or photo that can best show the design points: perspective view.

The present invention relates to a peptide complex having activities of preventing or treating fatty liver disease. The peptide complex of the present invention inhibits, in hepatocytes, the expression of fat synthesis-related genes and proteins and promotes the expression of fatty acid oxidation-related genes and proteins, and thus can inhibit, in hepatocytes, fat accumulation and promote lipolysis. In addition, the peptide complex of the present invention can inhibit the expression of inflammation-related genes in hepatocytes, and inhibits the expression of hepatotoxicity-related proteins, thereby having hepatoprotective activity. Furthermore, the peptide complex of the present invention can inhibit the degree of fat accumulation and liver fibrosis in liver tissue. Therefore, the peptide complex of the present invention is expected to be effectively used for preventing, alleviating or treating fatty liver disease.

This document describes the crystalline and liquid crystalline forms of sodium 25HC3S. This disclosure includes sodium 25HC3S in forms I, II, III, V, IX, XI, and XIII, and combinations thereof. Pharmaceutical formulations of the said forms or combinations thereof are further disclosed herein, as well as methods for treating or preventing diseases such as hypercholesterolemia, hypertriglyceridemia, and conditions associated with fat accumulation and inflammation (e.g., non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), alcoholic hepatitis, acute kidney injury (AKI), psoriasis, and atherosclerosis). Methods for preparing 25HC3S are also provided.

A biological function regulating agent comprises a fermented collagen peptide, and the fermented collagen peptide has at least one action selected from the group consisting of an epidermal metabolism promoting action, a fat accumulation inhibiting action, a fat decomposition promoting action and an action of regulating the amount of adipocytokine in a biological body.

The present invention relates to a composition for alleviating obesity or improving lipid metabolism, comprising a Rostellularia procumbens extract. The Rostellularia procumbens extract according to the present invention has the effects of inhibiting weight gain and fat accumulation and lowering blood levels of total triglycerides, total cholesterol, and low-density lipoprotein. In addition, the Rostellularia procumbens extract of the present invention, as a natural medicinal agent, can be applied to various products such as pharmaceutical compositions, food compositions, and feed compositions for the prevention, treatment, or alleviation of obesity or for the improvement of lipid metabolism.

The use of a postbiotic of Bifidobacterium brevis 207-1 (GDMCC No. 60962) or a composition containing the postbiotic in the preparation of a medicine or a food product. The medicine or food product is used for preventing and / or ameliorating diseases and / or symptoms related to fat gain in a subject. The diseases and / or symptoms are selected from weight gain, obesity, fatty liver, fat accumulation (e.g., visceral fat accumulation and subcutaneous fat accumulation), abnormal lipid metabolism, or any combination thereof. The medicine or food product can promote the fat breakdown and / or inhibit the fat absorption, maintain or reduce the body weight and / or BMI of the subject, increase the satiety of the subject, and reduce the food intake of the subject.

A biological function modifier, comprising fermented collagen peptides, said fermented collagen peptides having at least one effect selected from the group consisting of promoting epidermal metabolism, inhibiting fat accumulation, promoting fat breakdown, and regulating the amount of adipokines in the body.

The invention relates to the field of daily chemicals, and discloses a composite massage preparation as well as a preparation method and application thereof. The preparation is prepared by compounding recombinant human-derived III-type collagen, a high-activity pollen protein extract and traditional Chinese medicine herbal essence according to a specific proportion, the traditional Chinese medicine herbal essence is prepared by extracting and purifying 12 medicinal materials, and the contents of alkaloid, flavonoid and polysaccharide are respectively greater than or equal to 12%, 18% and 15%. The preparation technology comprises the following steps: preparing recombinant collagen through genetic engineering, extracting pollen protein through supercritical CO2, and carrying out low-temperature dynamic cycle extraction and molecular distillation purification on traditional Chinese medicine components. The preparation has a remarkable synergistic effect by promoting lipolysis, repairing skin injury and regulating the body state, and in-vitro, animal and human body tests prove that the preparation has excellent effects in the aspects of reducing fat accumulation, improving skin elasticity and assisting metabolism regulation. The composition can be prepared into various dosage forms, is used for shaping the body, beautifying the skin and conditioning sub-health, and is comprehensive in effect, high in safety and wide in market prospect.

The invention belongs to the technical field of biology, and discloses application of pranlukast in preparation of drugs for preventing and / or treating fatty liver diseases, diabetes and obesity. The invention proves that pranlukast has the effect of relieving fat accumulation in vivo and in vitro; the pranlukast can obviously reduce lipid droplet accumulation in liver cells at an in-vitro cellular level, obviously reduce the weight of a metabolism-related fatty liver disease (MASLD) model mouse induced by a high-fat feed in vivo, and improve pathological abnormalities such as liver functions, glucose and lipid metabolism disorder, insulin resistance and liver fatty degeneration; it shows potential in preventing or treating diseases accompanied by the metabolic syndrome. Meanwhile, the invention further provides a medicine which contains pranlukast and is used for preventing and / or treating the diseases.

The present invention relates to a pharmaceutical composition for preventing or treating obesity, and a food composition for preventing or improving obesity, comprising an extracellular vesicle derived from a Bifidobacterium spp. strain as an active ingredient. The composition of the present invention has the effect of reducing body weight in an obese animal model, reducing the amount of neutral fat in the liver and total cholesterol in the blood and the weight of white fat that are increased in an obese animal model, and reducing fat accumulation in the liver and brown adipose tissue and the size of white adipose cells without causing a decrease in appetite. In addition, the extracellular vesicle of the present invention has the effect of inhibiting fat synthesis in adipocytes that have induced fat accumulation. As such, the extracellular vesicle derived from a Bifidobacterium spp. strain of the present invention exhibits an excellent anti-obesity effect, and may be effectively utilized as a pharmaceutical composition for preventing or treating obesity.

A patent obtained in the earlier stage is that the line peptide COX52-69 is cyclized to realize an oral administration route. The invention finds that the cyclic peptide has the effect of reducing body weight. The invention is named as application of the polypeptide COX52-69 in reducing liver fat accumulation and fat cell volume. In the invention, a diet-induced obesity (DIO) model is established by feeding C57BL / 6J mice with high-fat feed (45% of fat for energy supply) for 14 weeks. After a DIO mouse is obtained, a 17-week administration experiment is carried out by using a PBS buffer solution and a Rybelsus solution as a contrast, and observation finds that the COX52-69 cyclic peptide can reduce liver fat accumulation and reduce the fat cell volume of fat tissue while reducing the weight of the DIO mouse. Therefore, the COX52-69 cyclic peptide has practical application in improving the volume of the fatty liver and the fat cells.

The invention relates to application of a fingered citron extract in preparation of a medicine for treating metabolic syndrome, and belongs to the technical field of biological medicines. According to the fingered citron extract disclosed by the invention, the diversity of flora can be improved by regulating intestinal flora, and the relative abundance of beneficial bacteria Akkermansia is specifically increased, so that the metabolic syndrome induced by high fat diet is relieved. An embodiment verifies that the scheme of the invention not only can significantly inhibit weight gain of obese mice induced by high fat diet, improve glucose metabolism disorder (including reduction of fasting blood-glucose and improvement of oral glucose tolerance), relieve liver fat accumulation and pathological damage, reduce visceral fat accumulation and improve adipocyte hypertrophy, but also can significantly inhibit the weight gain of the obese mice induced by high fat diet and improve the glucose metabolism disorder (including reduction of fasting blood-glucose and improvement of oral glucose tolerance). And obesity-related metabolic hormone disorder can be effectively reversed, for example, the serum insulin level is improved, and the leptin level is reduced.

The invention discloses garcinia cambogia fat-reducing and shaping health-care cream. Targeted delivery of active components (HCA, escin and the like) is realized through a nano-liposome drug-loading technology. In-vitro experiments prove that the fat decomposition rate (67.5%, Plt, 0.01) of the product can be remarkably increased, the transdermal absorption amount reaches 38.9 micrograms / cm < 3 >, and the stability of the paste is excellent (the retention rate of effective components is greater than 90% after 3-month acceleration at 40 DEG C). The composition is suitable for external application to improve local fat accumulation.

The disclosure is a peptide (Iaká (SEQ ID No1) with lightening action for periorbital hyperpigmentation, cosmetic or dermopharmaceutic composition containing this peptide and the use of this composition in the treatment of dark circles. Periorbital hyperpigmentation is a condition that does not add any risks to the patient's health state, however, it can cause aesthetic discomforts and appearance of tiredness. Dark circles can be formed due to anatomy or fat accumulation; due to a very thin skin thickness, allowing visualization of subcutaneous vessels; and, furthermore, due to melanin accumulation in the region. Due to this disclosure being a cosmetic composition, of topic non-invasive application, it can be applied daily without the requirement for an aesthetic specialist, besides not being as expensive as the currently known techniques for dark circles treatment. The peptide acts inhibiting melanogenesis.

The present invention relates to an anti-obesity composition comprising an extract of Rosa rugosa flower buds as an active ingredient, and by virtue of comprising the extract, aims to provide a composition having excellent anti-obesity efficacy by exhibiting the effects of inhibiting fat accumulation, reducing triglyceride content, increasing the expression of adipose triglyceride lipase (ATGL) and AMP-activated protein kinase (AMPK) proteins, and decreasing the expression of G0S2 (G0 / G1 switch 2) and perilipin proteins.

The present invention relates to the Bacteroides eggerthii KGMB05336 strain and a use thereof, wherein, through the analysis of the microbiome in patients with non-alcoholic fatty liver disease that is caused by obesity, the Bacteroides eggerthii strain was identified as a significant strain. Oral administration of the Bacteroides eggerthii strain to animal models of obesity and non-alcoholic fatty liver disease caused by obesity resulted in body weight reduction, liver weight reduction, decrease of fat accumulation in visceral and liver tissues, and reduction in serum levels of AST (U / L), ALT (U / L), cholesterol (mg / dL), and glucose (mg / dL), thus demonstrating that the Bacteroides eggerthii strain can serve as a novel means for the prevention, improvement, or treatment of obesity and diseases caused by obesity, such as fatty liver, hepatomegaly, non-alcoholic fatty liver disease, and diabetes.

The invention discloses a composition helpful for controlling in-vivo fat and application thereof, and relates to the technical field of biology. The hesperidin composition is prepared from hesperidin and lactobacillus johnsonii (Lactobacillus johnsonii), and the hesperidin composition is prepared from the hesperidin and the lactobacillus johnsonii. Research finds that the composition can achieve synergistic up-regulation of gene and protein expression of adipose tissue PGC1alpha and UCP1 and increase the body surface temperature; the composition can also significantly improve the bioavailability of hesperidin and improve the concentration of hesperetin and other metabolites in serum; the composition can also optimize the intestinal microecology, improve the intestinal flora structure, increase the lactobacillus colonization rate, enrich the abundance of beneficial bacteria and promote the generation of short-chain fatty acids; the composition can also significantly improve lipid metabolism disorder of an organism, reduce fat accumulation, regulate adiponectin and leptin levels, control fat in the body and realize effective weight loss management.

The present invention relates to a composition for body fat reduction containing extracts of Taraxacum platycarpum and Lonicerae japonica as active ingredients. It has been confirmed that a mixed extract of Taraxacum platycarpum and Lonicerae japonica according to the present invention reduces body weight and body fat when administered to mice with obesity induced by a high-fat diet. Also, it has been confirmed that the mixed extract reduces the size of fat tissue, reduces fat vacuoles (pore) in liver tissue, reduces total cholesterol, triglycerides, and LDL-cholesterol in the blood, and increases HDL-cholesterol. Furthermore, it has been confirmed that the mixed extract suppresses the expression of PPAR-γ which is related to fat synthesis. In addition, it has been confirmed that the mixed extract has a synergistic effect on the regulation of intracellular fat accumulation and fat metabolism factors in cells in which fat accumulation is induced.

The invention belongs to the technical field of intelligent wearable equipment, and provides intelligent weight-losing underwear and an intelligent control method thereof.The intelligent weight-losing underwear comprises an upper garment and a lower garment, the upper garment and the lower garment are each provided with a self-pressurization assembly, each self-pressurization assembly comprises a first micro air pump and a second micro air pump, and an air guide main path is fixedly installed at the output end of each first micro air pump; the tail end of the air guide main path is fixedly provided with a micro electromagnetic valve input end, the output end of the micro electromagnetic valve is fixedly provided with an air guide branch, the tail end of the air guide branch is fixedly provided with a flexible air bag, a pressure sensor is arranged in the flexible air bag, one side, close to the skin, of the flexible air bag is fixedly provided with an interlayer, and the other side of the interlayer is fixedly provided with convex blocks according to acupuncture points; the fat accumulation part is stimulated through pressurization, acupoint massage and far infrared hot compress are combined, the three-dimension synergistic effect of mechanical compression, meridian regulation and metabolism acceleration is achieved, and the weight losing effect is effectively improved.